BASEL, Switzerland & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cimeio Therapeutics, the leading biotechnology company in the field of epitope shielding, presented data for its CD45 and CD33 programs during ...
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies, presented data for its CD45 Shielded Cell & ...
CAR-T cell therapies have been heralded as a game changer for blood cancers, but those therapies approved so far have been focused on a few subtypes of leukemia, lymphoma and myeloma. Now, a new ...
Because CD45 is found on nearly all blood cells -- and is usually highly expressed on blood cancer cells -- a treatment that wipes out all CD45-bearing cells would leave patients without any blood ...
A broad new strategy could hold hope for treating virtually all blood cancers with CAR T cell therapy, which is currently approved for five subtypes of blood cancer. Scientists in the Perelman School ...
CD45 + C1q + CCR8+ cells may serve as a biomarker for kidney disease severity and progression risk, reflecting inflammation and fibrosis. Elevated levels of these cells correlate with serum creatinine ...
Dana-Farber Cancer Institute authors: Ali Salehi Farid, PharmD, Jennifer E. Rowley, Harris H. Allen, Isabella G. Kruger, Soheil Tavakolpour, Kyle Neeley, Min Cong ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results